2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-156596
    Aneratrigine 2097163-74-9 99.60%
    Aneratrigine is a selective Nav1.7 inhibitor with an IC50 of 19 nM. Aneratrigine is applicable for pain-related research.
    Aneratrigine
  • HY-156817
    TNIK-IN-6 2375196-40-8 98.28%
    TNIK-IN-6 (Compound 9) is an inhibitor of Traf2 and Nck-interacting kinase (TNIK) and , with IC50 of 0.93 μM, that plays important roles in neurological and psychiatric disorders.
    TNIK-IN-6
  • HY-157521
    AANAT-IN-1 3055162-52-9 99.87%
    AANAT-IN-1 is an arylalkylamine N-acetyltransferase (AANAT) inhibitor with a sheep AANAT IC50 of 9.9 μM. AANAT-IN-1 binds to the active site of sheep AANAT, interacting with amino acid residues via hydrogen bonds, hydrophobic interactions, ionic interactions, and water bridges, inhibiting the enzyme's catalytic activity. AANAT-IN-1 can be used for the researches of circadian rhythm-associated neuropsychiatric conditions, seasonal affective disorder, and other diseases associated with abnormally elevated melatonin levels.
    AANAT-IN-1
  • HY-157956
    LASSBio-873 873694-54-3 99.82%
    LASSBio-873 is an orally active muscarinic cholinergic receptor (mAChR) agonist that crosses the blood-brain barrier. LASSBio-873 has potent analgesic effects on acute and inflammatory pain. The analgesic effect of LASSBio-873 can be inhibited by intrathecal injection of the M2 receptor antagonist methoctramine.
    LASSBio-873
  • HY-157999
    SDI-118 1651179-19-9 98.86%
    SDI-118 is an orally active modulator for synaptic vesicle glycoprotein 2A (SV2A) with an IC50 of 13 nM.
    SDI-118
  • HY-160239
    HFI-437 1110650-74-2 99.64%
    HFI-437 is a potent non-peptidic insulin-regulated aminopeptidase (IRAP) inhibitor with a Ki of 20 nM. HFI-437 is a cognitive enhancer.
    HFI-437
  • HY-162076
    AEP-IN-3 2978521-26-3 99.71%
    AEP-IN-3 (compound 18) is an orally active, potent and brain penetrant asparagine endopeptidase (AEP) inhibitor, with an IC50 of 7.8 ± 0.9 nM. AEP-IN-3 can be used for Alzheimer’s Disease (AD) research.
    AEP-IN-3
  • HY-162666
    TMEM175 modulator 1 3038770-25-8 98.91%
    TMEM175 modulator 1 (compound 47) is a TMEM175 modulator.TMEM175 modulator 1 modulates activity of the lysosomal potassium ion channel TMEM175.TMEM175 modulator 1 can be used for the research of parkinson’s disease, dementia, alzheimer’s disease, l-dopa induced dyskinesia.
    TMEM175 modulator 1
  • HY-163145
    α-Synuclein inhibitor 11 3095291-54-3 98.0%
    α-Synuclein inhibitor 11 (compound 1) is a selective α-synuclein (α-syn) oligomer formation inhibitor. α-Synuclein inhibitor 11 does not inhibits tau 4R (isoforms 0N4R, 2N4R) or p-tau (isoform 1N4R). α-Synuclein inhibitor 11 can be used for Parkinson's disease (PD) research.
    α-Synuclein inhibitor 11
  • HY-163779
    β-Glucocerebrosidase modulator 1 3080715-77-8 99.01%
    β-Glucocerebrosidase modulator 1 (Compound 28) is an allosteric modulator for β-Glucocerebrosidase with an EC50 of 9.0 μM and a Kd of 0.050 μM.
    β-Glucocerebrosidase modulator 1
  • HY-164580
    RO3244794 361457-01-4 99.64%
    RO3244794 is a potent and selective IP (prostacyclin) receptor antagonist, with a pKi of 7.7 and 6.9 in human platelet and recombinant IP receptor system, respectively. RO3244794 exhibits analgesic and anti-inflammatory potential.
    RO3244794
  • HY-164926
    PARP1-IN-33 2640677-68-3 99.02%
    PARP1-IN-33 (Example 6) is a PARP1 inhibitor (IC50: 0.41 nM). PARP1-IN-33 has retinal cytoprotective effect, with an EC50 of 0.02 nM (inhibition on MTS activity of H2O2 induced human retinal pigment epithelial cell).
    PARP1-IN-33
  • HY-167830
    SDM-8 2242777-37-1 99.79%
    SDM-8 is a difluoro-analog of UCB-J (HY-136873).SDM-8 shows high SV2A binding affinity with a Ki of 0.58 nM. SDM-8 can be used in the study of Alzheimer's disease.
    SDM-8
  • HY-167851
    CCX662 1226686-54-9 98.62%
    CCX662 is a selective CXCR7 inhibitor with human IC50 values of 9 nM (buffer) and 18 nM (100% human serum), and rat IC50 of 14 nM (100% rat serum). CCX662 blocks CXCL12 binding to CXCR7, inhibits CXCR4-directed trans-endothelial migration of CXCR4+/CXCR7+ cells. CCX662 can be used for the research of glioblastoma multiforme.
    CCX662
  • HY-168366
    R-6890 3222-88-6 99.59%
    R-6890 is a Brorphine-related opioid receptor antagonist that exhibits differential binding activities toward rat opioid receptors (IC50=4.6 nM (0.05 M Tris; pH 7.4) and 170 nM (0.05 M Tris+0.1 M NaCl)). R-6890 displaces bound labeled opioids from receptors, and its binding affinity is affected by environmental factors, decreasing in the presence of NaCl. R-6890 crosses the blood-brain barrier (BBB) and exerts analgesic effects in the warm water-induced tail-flick reflex model of male Wistar rats.
    R-6890
  • HY-168906
    BI-113823 1119282-90-4 99.23%
    BI-113823 is an orally active, blood-brain barrier-permeable bradykinin B1 receptor antagonist, with a Ki value of 5.3 nM for human receptors and 13.3 nM for rat receptors. BI-113823 reduces inflammation-induced mechanical hyperalgesia, as well as the mechanical sensitivity of peripheral afferent nerves and spinal nociceptive-specific neurons. BI-113823 alleviates liver fibrosis and portal hypertension, and improves survival in chronic liver disease models. BI-113823 inhibits the activities of monocytes, neutrophils and hepatic stellate cells, as well as the PI3K/Akt signaling pathway. BI-113823 can be used in research related to inflammatory pain, liver fibrosis and portal hypertension.
    BI-113823
  • HY-169003
    STT3A/B-IN-1 3067184-99-7 99.15%
    STT3A/B-IN-1 is an orally active STT3A/B inhibitor with antiviral activity. STT3A/B-IN-1 upregulates DERL3 gene expression levels. STT3A/B-IN-1 is promising for research of viral diseases, including cancer and neurodegenerative disorders.
    STT3A/B-IN-1
  • HY-169116
    D5R agonist 1 99.83%
    D5R agonist 1 (Compound 5j) is a selective, orally active and BBB penetrable D5R partial agonist (EC50: 269.7 nM). D5R agonist 1 enhances the cognition in the Scopolamine (HY-N0296)-induced amnesia model.
    D5R agonist 1
  • HY-169345
    VU6043653 3032791-06-0 99.97%
    VU6043653 is a potent, selective and cross the blood-brain barrier metabotropic glutamate receptor subtype 5 (mGlu5) negative allosteric modulator with an IC50 value of 325 nM for h mGlu5.
    VU6043653
  • HY-170410
    EMD-95885 178165-43-0 98.74%
    EMD-95885 is a selective NR2B-containing NMDA receptors antagonist with an IC50 of 3.9 nM. EMD-95885 does not interact with other sites on the NMDA receptor.
    EMD-95885
Cat. No. Product Name / Synonyms Application Reactivity